Study: NCT01132313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 28 weeks, high dose, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 40 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 4 weeks, low dose TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 24 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 16 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 28 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 28 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 40 weeks, high dose, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks, very high dose, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks, standard dose, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 24 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 48 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 40 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks, high dose, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 28 weeks, high dose, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 28 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 16 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 24 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 28 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks, standard dose, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 24 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 16 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 16 weeks, high dose, BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 24 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 16 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 16 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207217
Description: 28 weeks, high dose BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 16 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 24 weeks, high dose, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 48 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: 4 weeks, high dose, TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 201335
Description: 28 weeks, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 weeks, according to label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 24 weeks, according to label